Compare AMRX & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMRX | FHI |
|---|---|---|
| Founded | 2002 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2018 | 1998 |
| Metric | AMRX | FHI |
|---|---|---|
| Price | $13.08 | $56.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | $15.60 | ★ $54.20 |
| AVG Volume (30 Days) | ★ 1.4M | 705.0K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | ★ 157.89 | 58.82 |
| EPS | 0.19 | ★ 1.27 |
| Revenue | N/A | ★ $1,102,924,000.00 |
| Revenue This Year | $4.48 | $9.90 |
| Revenue Next Year | $7.13 | $4.35 |
| P/E Ratio | $68.18 | ★ $43.54 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $41.55 |
| 52 Week High | $15.42 | $59.05 |
| Indicator | AMRX | FHI |
|---|---|---|
| Relative Strength Index (RSI) | 57.73 | 53.08 |
| Support Level | $12.45 | $51.62 |
| Resistance Level | $13.64 | $57.35 |
| Average True Range (ATR) | 0.34 | 1.45 |
| MACD | 0.07 | 0.21 |
| Stochastic Oscillator | 88.00 | 76.98 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Federated Hermes provides asset management services for institutional and individual investors. The firm had $902.6 billion in managed assets at the end of 2025, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (76%) funds. The firm's cash management operations are expected to generate around 55% of Federated's revenue this year, compared with 27%, 10%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (68% of AUM), institutional investors (25%), and international clients (7%).